{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T09:42:36Z","timestamp":1648892556229},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[1998,3,1]],"date-time":"1998-03-01T00:00:00Z","timestamp":888710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[1998,3]]},"DOI":"10.1016\/s1368-7646(98)80215-x","type":"journal-article","created":{"date-parts":[[2005,7,22]],"date-time":"2005-07-22T12:04:42Z","timestamp":1122033882000},"page":"59-61","source":"Crossref","is-referenced-by-count":7,"title":["Role of angiogenesis in the response to anticancer therapies"],"prefix":"10.1016","volume":"1","author":[{"given":"Beverly A.","family":"Teicher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S1368-7646(98)80215-X_bib1","first-page":"203","article-title":"Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies","volume":"24","author":"Pluda","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1016\/S1368-7646(98)80215-X_bib2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1699-0463.1997.tb00590.x","article-title":"Angiogenesis: new aspects relating to its initiation and control","volume":"105","author":"Norrby","year":"1997","journal-title":"APMIS"},{"key":"10.1016\/S1368-7646(98)80215-X_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1023\/A:1005714527315","article-title":"Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy","volume":"15","author":"Fox","year":"1997","journal-title":"Invest New Drugs"},{"key":"10.1016\/S1368-7646(98)80215-X_bib4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF00437466","article-title":"What, if anything, is an angiogenic factor?","volume":"15","author":"Risau","year":"1996","journal-title":"Cancer Metast Rev"},{"key":"10.1016\/S1368-7646(98)80215-X_bib5","first-page":"1","article-title":"Regulation of tumor angiogenesis by organ-specific cytokines","volume":"213","author":"Singh","year":"1996","journal-title":"Curr Topics Microbiol Immunol"},{"key":"10.1016\/S1368-7646(98)80215-X_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1023\/A:1005766511385","article-title":"Angiogenic factors as tumor markers","volume":"15","author":"Nguyen","year":"1997","journal-title":"Invest New Drugs"},{"key":"10.1016\/S1368-7646(98)80215-X_bib7","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0959-8049(96)00397-8","article-title":"Clinical significance of the determination of angiogenic factors","volume":"32A","author":"Toi","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/S1368-7646(98)80215-X_bib8","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/jnci\/88.16.1110","article-title":"Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma","volume":"88","author":"Takebayashi","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S1368-7646(98)80215-X_bib9","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/0959-8049(96)00061-5","article-title":"The activity and expression of thymidine phosphorylase in human solid tumours","volume":"32A","author":"Takebayashi","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/S1368-7646(98)80215-X_bib10","first-page":"4799","article-title":"Expression of the angiogenic factor thymidine phosphorylase\/platelet-derived endothelial cell growth factor in primary bladder cancers","volume":"56","author":"O'Brien","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/S1368-7646(98)80215-X_bib11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/bjc.1996.49","article-title":"The angiogenic factor platelet-derived endothelial cell growth factor\/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium","volume":"73","author":"Fox","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/S1368-7646(98)80215-X_bib12","first-page":"570","article-title":"The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor\/thymidine phosphorylase in human breast tumor cells growth in vitro and in vivo","volume":"57","author":"Griffiths","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/S1368-7646(98)80215-X_bib13","first-page":"3924","article-title":"Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells","volume":"57","author":"Yoshiji","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/S1368-7646(98)80215-X_bib14","doi-asserted-by":"crossref","first-page":"15442","DOI":"10.1074\/jbc.272.24.15442","article-title":"Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells","volume":"272","author":"Abedi","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/S1368-7646(98)80215-X_bib15","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1139\/o96-090","article-title":"A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth","volume":"74","author":"Anand-Apte","year":"1996","journal-title":"Biochem. Cell Biol."},{"key":"10.1016\/S1368-7646(98)80215-X_bib16","first-page":"679","article-title":"Effect of host microenvironment on the micro-circulation of human colon adenocarcinoma","volume":"151","author":"Fukumura","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1016\/S1368-7646(98)80215-X_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/10739689709148315","article-title":"Geometric resistance and microvascular network architecture of human colorectal carcinoma","volume":"4","author":"Less","year":"1997","journal-title":"Microcirculation"},{"key":"10.1016\/S1368-7646(98)80215-X_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10739689709148314","article-title":"The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors","volume":"4","author":"Jain","year":"1997","journal-title":"Microcirculation"},{"key":"10.1016\/S1368-7646(98)80215-X_bib19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF00437479","article-title":"A systems approach to cancer therapy","volume":"15","author":"Teicher","year":"1996","journal-title":"Cancer Metast Rev"},{"key":"10.1016\/S1368-7646(98)80215-X_bib20","first-page":"71","article-title":"Effects of novel and conventional anti-cancer agents on human endothelial permeability: influence on tumour secreted factors","volume":"17","author":"Watts","year":"1997","journal-title":"AntiCancer Res"},{"key":"10.1016\/S1368-7646(98)80215-X_bib21","first-page":"1829","article-title":"Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature","volume":"57","author":"Dark","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/S1368-7646(98)80215-X_bib22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/roi.2970020604","article-title":"Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy","volume":"2","author":"Teicher","year":"1995","journal-title":"Rad Oncol Invest"},{"key":"10.1016\/S1368-7646(98)80215-X_bib23","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0959-8049(96)00380-2","article-title":"TNP-470\/minocycline\/cytotoxic therapy: a systems approach to cancer therapy","volume":"32A","author":"Teicher","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/S1368-7646(98)80215-X_bib24","article-title":"Paclitaxel\/carboplatin administration along with antiangiogenic therapy in non-small cell lung and breast carcinoma models","author":"Herbst","year":"1997","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136876469880215X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136876469880215X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T04:56:45Z","timestamp":1548305805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S136876469880215X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,3]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1998,3]]}},"alternative-id":["S136876469880215X"],"URL":"https:\/\/doi.org\/10.1016\/s1368-7646(98)80215-x","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[1998,3]]}}}